HCPCS Level II code J1951 designates the injection of leuprolide acetate for depot suspension (fensolvi), 0.25 mg. This injectable GnRH agonist dosage unit is used in treatments requiring sustained suppression of gonadal steroid production, making it relevant across oncology, reproductive endocrinology, and certain chronic hormone-dependent conditions. Nationally, outpatient administration of depot hormone therapies represents a notable portion of drug-administered services billed to major public and commercial payers.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for J1951, typical sites of service, and payer scope. The publication also summarizes benchmarks and coverage considerations, outlines common billing modifiers and service-line context, and highlights areas where policy updates or coding clarifications frequently occur.

This resource is intended to inform billing staff, practice managers, and policy analysts about the code’s clinical purpose, billing context, and what to examine in payer-specific reimbursement and coverage policies. Data not available in the input will be noted where applicable.